source
- Zealand and Roche report positive Phase 2 results for amylin drug petrelintide in obesity and diabetesZealand Pharma and Roche announced topline results from a Phase 2 trial of their amylin analogue petrelintide in patients with obesity and type 2 diabetes. The interim data showed that participant…
- Roche signs near-$1 billion partnership with Chinese biotech Defand on degrader therapiesRoche has entered into a new collaboration with Defand, a relatively unknown biotech based in Hangzhou, China. The agreement is the fourth China-focused deal the Swiss drugmaker has signed since Au…